Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.60%, ranking 8th among 31 primary industries, outperforming the CSI 300 index which rose by 2.18% [4][16] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of January 9, 2026, is 30.56x, up from 29.20x at the end of the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries in terms of PE are vaccines (47.64x), hospitals (43.33x), and medical devices (39.44x), while pharmaceutical circulation has the lowest valuation at 15.42x [4][21] Industry Review - The report highlights significant developments in the pharmaceutical sector, including the release of the "Fourth Batch of Encouraged Generic Drug Catalog" aimed at optimizing the drug supply guarantee system and enhancing industry structure [6][26] - The report notes that 43 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 2.779 billion yuan, with 8 companies increasing holdings by 20 million yuan and 35 companies reducing holdings by 2.799 billion yuan [4] Important Industry News - The National Health Commission and other departments released the "Fourth Batch of Encouraged Generic Drug Catalog," which includes 21 varieties and 47 specifications, focusing on clinical needs and disease burdens [26][27] - The NMPA announced measures to strengthen the supervision and management of entrusted drug production, aiming to enhance drug quality assurance levels [29][30] - The NMPA also optimized the review and approval process for urgently needed overseas drugs, encouraging simultaneous global development and submission [31][32] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with strong pipeline differentiation, rapid clinical advancement, and robust overseas collaboration capabilities [7][8] - In the medical device sector, it recommends paying attention to companies with solid technical foundations and deep collaborations with leading hospitals and research institutions [8]

Core Viewpoint - Zai Jing Pharmaceutical has announced a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006, potentially generating up to $1.235 billion in revenue for the company [1][5]. Group 1: Financial Performance - Zai Jing Pharmaceutical reported a record revenue of 593 million yuan for the first three quarters of 2025, continuing a trend of rapid revenue growth since 2021 [1]. - Despite the revenue growth, the company has not achieved profitability since its IPO in 2020, accumulating a total net loss of 1.738 billion yuan by 2025 [8][9]. - The company has seen a decrease in R&D investment from 509 million yuan in 2021 to 388 million yuan in 2024, with a slight increase in 2025 [9]. Group 2: Strategic Developments - The collaboration with AbbVie grants the latter exclusive rights to develop and commercialize ZG006 outside Greater China, while Zai Jing retains rights within the region [4][5]. - ZG006 is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for small cell lung cancer and other DLL3-expressing malignancies [4]. - The agreement includes an upfront payment of $100 million and potential milestone payments totaling up to $1.235 billion, significantly enhancing the company's financial outlook [5]. Group 3: Market Position and Future Plans - Zai Jing Pharmaceutical is pursuing an IPO on the Hong Kong Stock Exchange to support its internationalization strategy and enhance brand recognition [2][10]. - The company aims to leverage the collaboration with AbbVie to expand ZG006 into multiple indications and improve its global market presence [5]. - The strategic focus includes addressing unmet medical needs in oncology and blood diseases, with a pipeline covering 29 projects [7].

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Core Insights - Suzhou Zelgen Biopharmaceutical Co., Ltd. has announced a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of its core product ZG006 (Alveltamig) [1] - AbbVie will obtain exclusive rights for ZG006 outside Greater China, while Zelgen retains all rights within Greater China [1] Financial Terms - Zelgen will receive an upfront payment of $100 million, with potential milestone payments up to $1.235 billion and tiered royalties [2] - The total potential amount from this collaboration could reach $1.235 billion (approximately 8.9 billion RMB), with the upfront payment already confirmed [2] - Royalties will be structured on a tiered basis, ranging from high single digits to mid-double digits based on net sales outside Greater China [2] Product Overview - ZG006 is a novel trispecific T-cell engager targeting DLL3 protein, currently in late-stage clinical development for small cell lung cancer and other DLL3-expressing malignancies [3] - The drug has received significant attention from regulatory agencies in both China and the U.S. due to the high malignancy of small cell lung cancer and limited existing treatment options [3] Strategic Significance - This collaboration represents a key implementation of Zelgen's strategy of "parallel independent research and open collaboration" [4] - By leveraging AbbVie's global clinical development and commercialization network, the international market expansion of ZG006 will be significantly accelerated [4] - The partnership also highlights the growing competitiveness of Chinese innovative pharmaceutical companies on the global stage [4]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致 的任何損失承擔任何責任。 Suzhou Zelgen Biopharmaceuticals Co., Ltd. 蘇州澤璟生物製藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （「本公司」） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本。本聆訊後資料集內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文 件，即代表 閣下知悉、接納並向本公司、獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定。該文件的文本將於發售期內供公眾人士查閱。 (a) 本文件僅向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中的 資料作出任何投資決定； (b) 在聯交 ...

Core Viewpoint - The announcement highlights the clinical data and latest progress of ZG006 and ZG005, which will be presented at the 2025 ASCO annual meeting, indicating the company's ongoing commitment to advancing its innovative oncology therapies [1]. Group 1: ZG006 Overview - ZG006, also known as Alveltamig, is a trispecific antibody drug developed by the company and its subsidiary, Gensun Biopharma Inc., targeting DLL3 and CD3, and has received orphan drug designation from the FDA [1][2]. - ZG006 is the first-in-class molecule targeting DLL3, showing potential to be a best-in-class therapy [1]. Group 2: ZG006 Clinical Data - In the ZG006-002 study, 48 patients with refractory advanced small cell lung cancer were randomized to receive either 10 mg or 30 mg Q2W treatment, with objective response rates (ORR) of 62.5% and 58.3%, respectively [2][3]. - The disease control rates (DCR) were 70.8% for the 10 mg group and 66.7% for the 30 mg group, with safety profiles showing no treatment-related adverse events leading to permanent discontinuation [3]. - In the ZG006-001 study, 47 patients received varying doses of ZG006, with confirmed ORR of 75.0% for 10 mg, 53.8% for 30 mg, and 58.3% for 60 mg, indicating strong anti-tumor activity [4][5]. Group 3: ZG005 Overview - ZG005, known as Nilvanstomig, is a recombinant humanized bispecific antibody targeting PD-1 and TIGIT, positioned as an innovative immunotherapy for various solid tumors [6][7]. - ZG005 is among the first of its kind to enter clinical research globally, with no similar mechanism drugs approved yet [6]. Group 4: ZG005 Clinical Data - In the ZG005-001 study, 55 patients with advanced cervical cancer were treated, showing an ORR of 40.9% and DCR of 68.2% in the 20 mg/kg group [7]. - The safety profile was favorable, with 83.6% of patients experiencing treatment-related adverse events (TRAE), predominantly grade 1-2 [7]. - In the ZG005-003 study, 60 patients with first-line cervical cancer were treated, with the 20 mg/kg group showing an ORR of 82.1% and DCR of 96.4% [8][9]. Group 5: ZGGS15 Overview - ZGGS15 is a recombinant humanized bispecific antibody targeting LAG-3 and TIGIT, representing a novel approach in tumor immunotherapy [10][11]. - It is the first of its kind to enter clinical research globally, with no similar mechanism drugs approved yet [10]. Group 6: ZGGS15 Clinical Data - In the ZGGS15-001 study, 22 patients were enrolled, with a DCR of 35.3% among evaluable patients [12]. - The safety profile showed that 90.1% of patients experienced TRAE, with no dose-limiting toxicities observed [12][13].